QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ARQT

QT77Arcutis Biotherapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
26.21
-0.01-0.04%
OverviewShort InterestFilings
ARQTQT77Arcutis Biotherapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
26.21-0.04%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-0.03
Insider Own20.95%
Shs Outstand125.08M
Perf Week6.59%
Market Cap3.28BForward P/E24.52EPS next Y1.07Insider Trans-0.13%Shs Float-Perf Month34.41%
Enterprise Value3.26BPEG-EPS next Q0.07Inst Own-Short Float-Perf Quarter14.40%
Income-2295773.00P/S7.89EPS this Y763.53%Inst Trans-Short Ratio-Perf Half Y-8.13%
Sales415.62MP/B17.89EPS next Y436.90%ROA-0.52%Short Interest-Perf YTD-9.75%
Book/sh1.52P/C125.66EPS next 5Y95.42%ROE-1.41%52W High31.77 -17.50%Perf Year97.66%
Cash/sh1.79P/FCF121.85EPS past 3/5Y-ROIC1.05%52W Low13.06 100.69%Perf 3Y-
Dividend Est.-EV/EBITDA216.80Sales past 3/5Y354.68% -Gross Margin90.94%Volatility3.14% 3.06%Perf 5Y-
Dividend TTM-EV/Sales7.84EPS Y/Y TTM97.41%Oper. Margin0.77%ATR (14)1.13Perf 10Y-
Dividend Ex-Date-Quick Ratio2.46Sales Y/Y TTM111.17%Profit Margin-0.57%RSI (14)71.87Recom2.17
Dividend Gr. 3/5Y-Current Ratio2.68EPS Q/Q55.00%SMA2015.45%Beta1.43Target Price34.00
Payout0.00%Debt/Eq0.07Sales Q/Q59.09%SMA5015.15%Rel Volume3.15Prev Close26.22
Employees342LT Debt/Eq0.03EarningsAug 05SMA2009.21%Avg Volume1.73MPrice26.21
IPO DateJan 31, 2020Option/ShortYes / YesEPS/Sales Surpr.-350.00% 0.96%Net Debt/EBITDA-1.43Volume5,462,002Change-0.04%
Analyst Ratings
DateActionAnalystRatingTarget
Feb-26-26ReiteratedH.C. Wainwright$30 → $34
Nov-28-25ReiteratedMizuho Securities$32 → $37
Oct-30-25ReiteratedGoldman SachsNeutral$37 → $29
Oct-29-25ReiteratedH.C. Wainwright$22 → $30
Oct-29-25ReiteratedMizuho Securities$18 → $32
Mar-11-25ReiteratedJefferiesBuy$19
Dec-30-24InitiatedH.CBuy$19
May-15-24ReiteratedMizuho Securities$8.00 → $18
May-15-24ReiteratedNeedhamBuy$18
Jan-03-24UpgradeMizuhoNeutral → Buy
Latest News
Jun-12-26
Jun-12-2601:15AM
Is Arcutis (ARQT) Using Genital Psoriasis Education to Quietly Reshape Its Dermatology Strategy?Yahoo
Jun-10-26
Jun-10-2612:02AM
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive StatusYahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue416376197
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A383719
Gross Profit379339177
Selling, General and Administrative Excl. Other284275229
Research and Development907776
Other Operating Expense101
Operating Income3-12-128
Interest Expense131227
Unusual Expense
———
Non-Operating Income (Expense)-8-9-16
Net Income Before Taxes-2-15-139
Income Taxes011
Consolidated Net Income-3-16-140
Net Income From Continuing Operations-3-16-140
Net Income-3-16-140
EPS (Recurring)-0.02-0.13-1.16
EPS (Basic, Before Extraordinaries)-0.02-0.13-1.16
EPS (Diluted)-0.03-0.13-1.16
EBITDA152-110
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio8.139.81—
Gross Margin91.1190.1689.85
Operating Margin0.72-3.19-64.97
Net Margin-0.72-4.26-71.07
Shares Outstanding129127121
Market Capitalization3,3813,688—
Operating Lease Expense
———
Insider Trading Volume
$27.80$24.47$21.14$17.81$14.48● Close Price0.00M1.45M2.89M4.34M5.79MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Welgus Howard G.DirectorJun 17 '26Sale25.6763516,30037,743Jun 17 12:00 AM
Welgus Howard G.DirectorJun 15 '26Option Exercise7.938,19264,95042,474Jun 17 12:00 AM
Welgus Howard G.DirectorJun 15 '26Sale24.414,09699,98038,378Jun 17 12:00 AM
LIN SUE-JEANDirectorJun 15 '26Sale24.384,946120,58727,567Jun 17 12:00 AM
Vairavan LathaSVP Chief Financial OfficerMay 11 '26Sale21.054359,15785,978May 13 12:00 AM
Burnett PatrickSee RemarksMay 11 '26Sale21.052224,673120,244May 13 12:00 AM
Matsuda MasaruSee RemarksMay 04 '26Sale23.318,256192,415126,689May 06 12:00 AM
Burnett PatrickSee RemarksMay 04 '26Sale23.6168416,150120,466May 06 12:00 AM
Vairavan LathaSVP Chief Financial OfficerMay 04 '26Sale23.611,34131,66286,413May 06 12:00 AM
Watanabe ToddSee RemarksMay 04 '26Sale23.613,17274,893720,755May 06 12:00 AM
Welgus Howard G.DirectorMay 01 '26Sale22.997,144164,22032,600May 05 12:00 AM
Welgus Howard G.DirectorApr 01 '26Sale23.8810,000238,80139,744Apr 03 12:00 AM
Leonard Keith RDirectorMar 02 '26Option Exercise8.2878,544650,46261,395Mar 04 12:00 AM
Leonard Keith RDirectorMar 02 '26Sale25.3939,272997,19522,123Mar 04 12:00 AM
Welgus Howard G.DirectorMar 02 '26Sale25.6510,000256,51849,744Mar 04 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR